U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H35FN2O5
Molecular Weight 558.641
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATORVASTATIN

SMILES

CC(C)c1c(c(-c2ccccc2)c(-c3ccc(cc3)F)n1CC[C@]([H])(C[C@]([H])(CC(=O)O)O)O)C(=Nc4ccccc4)O

InChI

InChIKey=XUKUURHRXDUEBC-KAYWLYCHSA-N
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H35FN2O5
Molecular Weight 558.641
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/mesh/2009919

Atorvastatin calcium (LIPITOR®) is a pyrrole and heptanoic acid derivative, a synthetic lipid-lowering agent. Atorvastatin is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. Atorvastatin is used to reduce serum levels of LDL(low-density lipoprotein)-cholesterol; apolipoprotein B; and triglycerides and to increase serum levels of HDL(high-density lipoprotein)-cholesterol in the treatment of hyperlipidemias and prevention of cardiovascular disease in patients with multiple risk factors.

Originator

Curator's Comment:: In 2000 Pfizer bought Warner-Lambert along with all of its subsidiary companies.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
14 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
LIPITOR

Approved Use

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. Atorvastatin calcium tablets are an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors (1.1). Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors (1.1). Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD (1.1). Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (1.2). Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia (1.2). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) (1.2). Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy (1.2). Limitations of Use Atorvastatin calcium tablets have not been studied in Fredrickson Types I and V dyslipidemias. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Types IIa and IIb); Fredrickson As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Type IV); Fredrickson For the treatment of patients with primary dysbetalipoproteinemia ( Type III) who do not respond adequately to diet; Fredrickson To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.

Launch Date

850780800000
Primary
LIPITOR

Approved Use

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. Atorvastatin calcium tablets are an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors (1.1). Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors (1.1). Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD (1.1). Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (1.2). Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia (1.2). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) (1.2). Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy (1.2). Limitations of Use Atorvastatin calcium tablets have not been studied in Fredrickson Types I and V dyslipidemias. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Types IIa and IIb); Fredrickson As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Type IV); Fredrickson For the treatment of patients with primary dysbetalipoproteinemia ( Type III) who do not respond adequately to diet; Fredrickson To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.

Launch Date

850780800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.8 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATORVASTATIN blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
9.52 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATORVASTATIN blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
33.24 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: oral
experiment type: single
co-administered:
ATORVASTATIN plasma
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
45 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATORVASTATIN blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
35.04 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATORVASTATIN blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
140.79 ng*h/mL
80 mg single, oral
dose: 80 mg
route of administration: oral
experiment type: single
co-administered:
ATORVASTATIN plasma
Homo sapiens
137.49 ng*h/mL
80 mg single, oral
dose: 80 mg
route of administration: oral
experiment type: single
co-administered:
ATORVASTATIN plasma
Homo sapiens
142.86 ng*h/mL
80 mg single, oral
dose: 80 mg
route of administration: oral
experiment type: single
co-administered:
ATORVASTATIN plasma
Homo sapiens
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.2 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATORVASTATIN blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
16.57 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATORVASTATIN blood
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.21 h
80 mg single, oral
dose: 80 mg
route of administration: oral
experiment type: single
co-administered:
ATORVASTATIN plasma
Homo sapiens
PubMed

PubMed

TitleDatePubMed
Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
1999 Nov
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.
2001
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
2001
The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial.
2001 Apr
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
2001 Apr
Linear IgA bullous dermatosis induced by atorvastatin.
2001 Apr
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
2001 Apr
Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans.
2001 Apr 16
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
2001 Apr 17
[Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
2001 Apr 5
Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
2001 Aug
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
2001 Aug
Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.
2001 Aug
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
2001 Aug 1
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
2001 Feb
Drug therapy or coronary angioplasty for the treatment of coronary artery disease: new insights.
2001 Feb
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
2001 Feb 1
Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia.
2001 Feb 1
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
2001 Feb 1
Celecoxib-induced cholestatic hepatitis.
2001 Feb 6
Aggressive LDL-cholesterol lowering with atorvastatin results in regression of atherosclerosis.
2001 Feb-Mar
[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
2001 Jan
[Lymphocyte infiltration in superficial dermis].
2001 Jan
Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs.
2001 Jan
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
2001 Jan
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
2001 Jan
Statins in children: what do we know and what do we need to do?
2001 Jan
New statins and new doses of older statins.
2001 Jan
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
2001 Jan 1
Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
2001 Jan 2
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.
2001 Jul
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
2001 Jul
Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
2001 Jul
Statin-stimulated nitric oxide release from endothelium.
2001 Jul-Aug
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
2001 Jun
Low-density lipoprotein apheresis in a patient aged 3.5 years.
2001 Jun
Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial.
2001 Jun
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
2001 Jun
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
2001 Jun
Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.
2001 Jun 19
[AVERT [The Atorvastatin versus Revascularization Treatment]].
2001 Mar
Statin therapy--what now?
2001 Mar
HMG-CoA reductase inhibitors and P-glycoprotein modulation.
2001 Mar
Tachyphylaxis and statin drugs.
2001 Mar 1
Dermographism: an adverse effect of atorvastatin.
2001 Mar-Apr
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
2001 May
Atorvastatin.
2001 May
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
2001 May
Genetic analysis of digestive physiology using fluorescent phospholipid reporters.
2001 May 18
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
2001 Spring
Patents

Sample Use Guides

The recommended starting dose of atorvastatin calcium (LIPITOR®) is 10 or 20 mg once daily. Patients who require a large reduction in LDL(low-density lipoprotein)-cholesterol (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium is 10 to 80 mg once daily. Atorvastatin calcium can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatinc calcium, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
Route of Administration: Oral
In Vitro Use Guide
In vitro, atorvastatin (CI-981) was equipotent as HMG-CoA reductase inhibitor in rat liver, spleen, testis and adrenal tissue (IC50 38.7 nM, 29.5 nM, 36.4, and 100.4 nM, respectively).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:38:27 UTC 2021
Edited
by admin
on Fri Jun 25 21:38:27 UTC 2021
Record UNII
A0JWA85V8F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATORVASTATIN
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
ATORVASTATIN [WHO-DD]
Common Name English
ATORVASTATIN [HSDB]
Common Name English
(.BETA.R,.DELTA.R)-2-(P-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)PYRROLE-1-HEPTANOIC ACID
Common Name English
1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (R-(R*,R*))-
Common Name English
ATORVASTATIN [MI]
Common Name English
ATORVASTATIN [INN]
Common Name English
ATORVASTATIN [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QC10BX03
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10AA05
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-VATC QC10AA05
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BX08
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
LIVERTOX 72
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
NDF-RT N0000175589
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
NCI_THESAURUS C1655
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BX11
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BA05
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BX03
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BX06
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-VATC QC10BA05
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BX15
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
NDF-RT N0000000121
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
WHO-ATC C10BX12
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1487
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
IUPHAR
2949
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
INN
7259
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
RXCUI
83367
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB01076
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
NCI_THESAURUS
C61527
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
MERCK INDEX
M2125
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY Merck Index
PUBCHEM
60823
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
LACTMED
Atorvastatin
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
MESH
C065179
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
HSDB
7039
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
CAS
134523-00-5
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
FDA UNII
A0JWA85V8F
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
EVMPD
SUB05600MIG
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
DRUG CENTRAL
257
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
WIKIPEDIA
Atorvastatin
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
EPA CompTox
134523-00-5
Created by admin on Fri Jun 25 21:38:27 UTC 2021 , Edited by admin on Fri Jun 25 21:38:27 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
RACEMATE -> ENANTIOMER
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
PARENT -> SALT/SOLVATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC HMG-CoA REDUCTASE INHIBITORY ACTIVITY

Biological Half-life PHARMACOKINETIC